<DOC>
	<DOCNO>NCT00333385</DOCNO>
	<brief_summary>The aim trial compare safety efficacy course tobramycin ceftazidime , administer intravenously either thrice daily short infusion 24 h continuous infusion , cystic fibrosis patient acute exacerbation chronic pulmonary PA infection . In conventional treatment regimen , ceftazidime administer form thrice daily short infusion , pharmacodynamic consideration suggest continuous infusion could effective .</brief_summary>
	<brief_title>Continuous Versus Short Infusions Ceftazidime Cystic Fibrosis</brief_title>
	<detailed_description>Each patient receive two successive IV antibiotic course period pulmonary exacerbation . One course deliver thrice daily 30-minute infusion ceftazidime 100 ml 0.9 % sodium chloride , deliver continuous infusion ceftazidime 230 ml 0.9 % sodium chloride , 23 hour . The daily dose ceftazidime 200 mg/kg , maximum dose 12 g. For ceftazidime continuous infusion , load dose 60 mg/kg ( maximum 2 g ) use . All patient also receive tobramycin ( 10 mg/kg ) , form one 30-minute infusion per day . Portable device use : Intermate® SV 200 ( Baxter ) 30-minute short infusion ceftazidime tobramycin , Infusor® LV10 ( Baxter ) continuous infusion ceftazidime .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<criteria>patient cystic fibrosis old 8 year chronic Pseudomonas aeruginosa infection respiratory tract least 2 course IV antibiotic year enrolment time pulmonary exacerbation allergy ceftazidime tobramycin bronchial colonization Burkholderia cepacia renal impairment history lung transplantation</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>Ceftazidime</keyword>
	<keyword>Continuous infusion</keyword>
	<keyword>Antibiotic course</keyword>
</DOC>